Cargando…
Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction
BACKGROUND: The epidermal growth factor receptor (EGFR) inhibitor, gefitinib, has been reported to successfully treat advanced non-small cell lung cancer patients with genetic mutations in EGFR. The aim of this study was to investigate the existence of EGFR mutations in carcinoma of esophagogastric...
Autores principales: | Wang, Wen-Ping, Wang, Kang-Ning, Gao, Qiang, Chen, Long-Qi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278359/ https://www.ncbi.nlm.nih.gov/pubmed/22252115 http://dx.doi.org/10.1186/1477-7819-10-14 |
Ejemplares similares
-
Integrative proteomic characterization of adenocarcinoma of esophagogastric junction
por: Li, Shengli, et al.
Publicado: (2023) -
Current surgical treatment of esophagogastric junction adenocarcinoma
por: Zhang, Shun, et al.
Publicado: (2019) -
Priority of lymph node dissection for advanced esophagogastric junction adenocarcinoma with the tumor center located below the esophagogastric junction
por: Cai, Ming-Zhi, et al.
Publicado: (2019) -
Investigation of BTLA tagging variants with risk of esophagogastric junction adenocarcinoma
por: Tang, Weifeng, et al.
Publicado: (2019) -
HN1L promotes invasion and metastasis of the esophagogastric junction adenocarcinoma
por: Wang, Zhao Yang, et al.
Publicado: (2021)